Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077522 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPK1L3MBTL1ALOX5FAAH | |
| SCHEMBL6077517 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPK1L3MBTL1ALOX5FAAH | |
| SCHEMBL1357622 | 0.88 | TP53 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL27156506 | 0.88 | TP53 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL10126870 | 0.85 | KMT2A (0.42) | ALDH1A1ALOX5KMT2A | |
| SCHEMBL18045294 | 0.85 | KMT2A (0.42) | ALDH1A1ALOX5KMT2A | |
| SCHEMBL12344914 | 0.82 | ALOX5 (0.41) | ALOX5KMT2A | |
| SCHEMBL13624815 | 0.82 | ALOX5 (0.41) | ALOX5KMT2A | |
| SCHEMBL18076669 | 0.80 | KMT2A (0.41) | ALDH1A1ALOX5KMT2A | |
| SCHEMBL6823126 | 0.75 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| WO-2004032834-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | ALDH1A1 1587/4885MAPK1 250/4885L3MBTL1 1069/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | ALDH1A1 2495/4885MAPK1 692/4885L3MBTL1 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.